Second Department of Intensive Care Medicine, George Papanikolaou General Hospital, Thessaloniki, Greece -
First Department of Intensive Care Medicine, George Papanikolaou General Hospital, Thessaloniki, Greece.
Minerva Anestesiol. 2021 Nov;87(11):1239-1254. doi: 10.23736/S0375-9393.21.15755-4. Epub 2021 Aug 2.
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a common and potentially fatal complication in the Intensive Care Unit (ICU). Critically ill patients have some special characteristics that increase the risk for VTE and complicate risk stratification and diagnosis. Given the positive effect of thromboprophylaxis on main outcomes, its use is mandatory in these patients, which is documented by various studies and recommended by all published guidelines. However, anticoagulation management is not an easy issue in clinical practice, as the critical patient may be at high risk for thrombosis or, conversely, at increased risk of bleeding or may balance between thrombotic and bleeding risk. Thrombotic and bleeding risk scoring should be evaluated daily in order to select the appropriate form of thromboprophylaxis. The selection depends on the degree of bleeding risk and the subgroup of ICU patients involved, such as patients with sepsis, acute brain injury, major trauma or COVID-2019. If there is no bleeding risk or other contraindication, the patient should receive pharmacologic thromboprophylaxis with unfractionated heparin or low molecular weight heparins, weighing the advantages of each agent. If the patient is at high risk of bleeding or there is a contraindication to pharmacologic prophylaxis, he should receive mechanical thromboprophylaxis mainly with intermittent pneumatic compression or graduated compression stockings. Thromboprophylaxis compliance with the guidelines is a prerequisite for moving from theory to practice. Direct oral anticoagulants have been studied in ICU patients and have no place at present in VTE prophylaxis requiring further research.
静脉血栓栓塞症(VTE),包括深静脉血栓形成和肺栓塞,是重症监护病房(ICU)中常见且潜在致命的并发症。危重症患者具有一些特殊特征,这些特征会增加 VTE 的风险,并使风险分层和诊断复杂化。鉴于血栓预防对主要结局的积极影响,各种研究证明在这些患者中使用它是强制性的,所有已发表的指南都推荐使用。然而,抗凝管理在临床实践中并不是一个简单的问题,因为危重症患者可能存在高血栓形成风险,或者相反,存在增加的出血风险,或者可能在血栓形成和出血风险之间平衡。应每天评估血栓形成和出血风险评分,以选择适当的血栓预防形式。选择取决于出血风险的程度和涉及的 ICU 患者亚组,例如脓毒症、急性脑损伤、重大创伤或 COVID-19 患者。如果没有出血风险或其他禁忌证,患者应接受普通肝素或低分子量肝素的药物性血栓预防,权衡每种药物的优势。如果患者出血风险高或存在药物预防禁忌证,则应主要使用间歇充气加压或分级加压弹力袜进行机械性血栓预防。指南指导下的血栓预防依从性是从理论走向实践的前提。直接口服抗凝剂已在 ICU 患者中进行了研究,但目前在需要进一步研究的 VTE 预防中没有地位。